- Home
- ZURA vs AVIR Comparison
ZURA vs AVIR Comparison
Compare ZURA & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZURA
- AVIR
- Stock Information
- Founded
- ZURA 2022
- AVIR 2012
- Country
- ZURA United States
- AVIR United States
- Employees
- ZURA N/A
- AVIR N/A
- Industry
- ZURA Biotechnology: Biological Products (No Diagnostic Substances)
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- ZURA Health Care
- AVIR Health Care
- Exchange
- ZURA Nasdaq
- AVIR Nasdaq
- Market Cap
- ZURA 292.1M
- AVIR 247.5M
- IPO Year
- ZURA N/A
- AVIR 2020
- Fundamental
- Price
- ZURA $2.88
- AVIR $2.94
- Analyst Decision
- ZURA Buy
- AVIR Hold
- Analyst Count
- ZURA 6
- AVIR 1
- Target Price
- ZURA $15.80
- AVIR $6.88
- AVG Volume (30 Days)
- ZURA 390.6K
- AVIR 227.6K
- Earning Date
- ZURA 11-07-2024
- AVIR 11-07-2024
- Dividend Yield
- ZURA N/A
- AVIR N/A
- EPS Growth
- ZURA N/A
- AVIR N/A
- EPS
- ZURA N/A
- AVIR N/A
- Revenue
- ZURA N/A
- AVIR N/A
- Revenue This Year
- ZURA N/A
- AVIR N/A
- Revenue Next Year
- ZURA N/A
- AVIR N/A
- P/E Ratio
- ZURA N/A
- AVIR N/A
- Revenue Growth
- ZURA N/A
- AVIR N/A
- 52 Week Low
- ZURA $2.00
- AVIR $2.86
- 52 Week High
- ZURA $6.35
- AVIR $4.60
- Technical
- Relative Strength Index (RSI)
- ZURA 36.44
- AVIR 34.81
- Support Level
- ZURA $2.71
- AVIR $2.86
- Resistance Level
- ZURA $2.87
- AVIR $3.54
- Average True Range (ATR)
- ZURA 0.23
- AVIR 0.14
- MACD
- ZURA -0.01
- AVIR -0.03
- Stochastic Oscillator
- ZURA 31.51
- AVIR 11.76
About ZURA Zura Bio Limited
Zura Bio Ltd is a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).